Sensei Biotherapeutics Announces $30 Million Financing to Advance Clinical Pipeline of Oncology Therapeutics and Proprietary ImmunoPhage™ Platform
Summary
BOSTON & ROCKVILLE, Md.--(BUSINESS WIRE)-- Sensei Biotherapeutics, Inc., a clinical-stage cancer immunotherapy company, today announced the successful closing of a $30 million Series B financing. This is a critical improvement over the months it takes for existing personalized approaches in cancer, where every day matters for patients,” said John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics. Sensei’s lead ImmunoPhage product candidate, SNS‑301, is being evaluated in a Phase 1/2 trial for the treatment of locally advanced unresectable or metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with pembrolizumab. Christian Angermayer, founder of Apeiron Investment Group, said, “Sensei’s approach has the realistic potential to overcome the prior challenges of cancer immunotherapy and make advancements we previously couldn’t dream of. Using its proprietary ImmunoPhage™ platform, Sensei is developing a library of ImmunoPhage called Phortress™ targeting multiple tumor associated antigens to treat patients using a personalized yet off the shelf cocktail approach.